Immunodeficiency 88 (IMD88) Cell Models for Research

Immunodeficiency 88 (IMD88) is a rare primary immunodeficiency disorder caused by mutations in the ZAP70 gene. The exact prevalence is unknown, but it is estimated to affect less than 1 in 1,000,000 individuals worldwide (WHO, 2023). The condition is characterized by severe combined immunodeficiency (SCID) with profound T cell lymphopenia and defective T cell receptor (TCR) signaling. Without early diagnosis and treatment, affected individuals typically succumb to recurrent infections within the first two years of life. Hematopoietic stem cell transplantation (HSCT) is the only curative therapy, but outcomes depend on early intervention. The rarity and severity of IMD88 underscore the need for robust research models to understand disease mechanisms and develop targeted therapies.

IMD88 serves as an excellent model for studying T cell development, TCR signaling, and immune tolerance. The ZAP70 kinase is a central node in the TCR signaling cascade, and its deficiency leads to a complete block in T cell maturation. Research on IMD88 has provided insights into the molecular requirements for T cell function and has implications for autoimmune diseases and cancer immunotherapy. Public datasets, such as those from the International Union of Immunological Societies (IUIS) and the European Society for Immunodeficiencies (ESID), provide clinical and genetic data that can be leveraged for mechanistic studies. Open questions include the precise role of ZAP70 in regulatory T cell function and the potential for gene therapy approaches.

While IMD88 is not a cancer, the molecular pathways involved are critical for immune cell function and are often dysregulated in hematological malignancies. The primary pathway affected is the TCR signaling pathway, which is essential for T cell activation and proliferation. Key steps include:

1. TCR engagement by peptide-MHC complexes.

2. Activation of Lck, which phosphorylates ITAMs on CD3 chains.

3. Recruitment of ZAP70 to the phosphorylated ITAMs via its SH2 domains.

4. Phosphorylation of downstream adaptors LAT and SLP-76.

5. Activation of downstream effectors such as PLCγ1, Ras, and NF-κB.

In IMD88, mutations in ZAP70 disrupt this cascade, leading to impaired calcium flux, MAPK activation, and cytokine production. Additionally, ZAP70 is involved in thymic selection and the maintenance of peripheral T cell tolerance.

Data from ClinVar and the Human Gene Mutation Database (HGMD) indicate that over 30 distinct pathogenic variants have been reported in ZAP70, with the most common being missense mutations in the kinase domain. These mutations impair ATP binding or catalytic activity, resulting in a functional knockout phenotype.

The deficiency of ZAP70 disrupts multiple downstream signaling networks:

• • Calcium signaling: Impaired PLCγ1 activation leads to reduced IP3 production and calcium flux, affecting NFAT translocation.
• • MAPK pathway: Reduced Ras activation leads to decreased ERK phosphorylation, impacting cell proliferation.
• • NF-κB pathway: Defective PKCθ activation results in impaired IKK complex activation and reduced NF-κB nuclear translocation.
• • Actin cytoskeleton reorganization: ZAP70 is required for actin polymerization and immunological synapse formation, which is critical for T cell activation.

These disruptions collectively lead to a block in T cell development and function, as observed in IMD88 patients.

Organoid models of the thymus are being developed to study T cell development in a 3D context. These organoids can be derived from induced pluripotent stem cells (iPSCs) and genetically edited to carry ZAP70 mutations, providing a more physiologically relevant platform for drug testing and mechanistic studies.

• • ZAP70 knockout mouse: A genetically engineered mouse model (GEMM) that recapitulates the human IMD88 phenotype, with a block in T cell development at the double-positive stage.
• • ZAP70 mutant mouse (SKG): A spontaneous point mutation in ZAP70 (W163C) that leads to autoimmune arthritis, useful for studying the role of ZAP70 in autoimmunity.
• • Patient-derived xenograft (PDX): Not commonly used for IMD88 due to the lack of tumor tissue, but iPSC-derived T cells can be transplanted into immunodeficient mice to study human T cell development.
• • Induced models: CRISPR-engineered cell lines with ZAP70 knockout or knock-in mutations are used for in vitro studies.

CRISPR-Cas9 gene editing has enabled the generation of isogenic cell lines with precise ZAP70 mutations. For example, a ZAP70 knockout Jurkat cell line can be created by introducing a frameshift mutation in exon 2, resulting in loss of protein expression. Alternatively, a knock-in cell line can be generated to introduce a specific pathogenic point mutation, such as R192W, to study its impact on kinase activity. These gene-edited models are commercially available and are sequence-verified to ensure accuracy. They are invaluable for studying the molecular consequences of ZAP70 mutations and for screening potential therapeutic compounds that can restore T cell function.

Gene-edited cell lines are essential for functional genomics studies to validate the role of ZAP70 in T cell signaling. For example, ZAP70 knockout Jurkat cells can be used to confirm the requirement of ZAP70 for TCR-induced calcium flux and IL-2 production. Conversely, knock-in cell lines expressing mutant ZAP70 can be used to assess the impact of specific mutations on downstream signaling pathways. These models enable researchers to dissect the structure-function relationship of ZAP70 and identify potential therapeutic targets.

Isogenic pairs of ZAP70 wild-type and knockout cell lines are powerful tools for drug screening. They can be used to identify compounds that selectively kill ZAP70-deficient cells or that rescue T cell function. For example, a high-throughput screen could identify small molecules that bypass the ZAP70 block and activate downstream signaling. Additionally, gene-edited models can be used to study resistance mechanisms to TCR signaling inhibitors, which are being explored as immunosuppressive agents.

CRISPR synthetic lethality screens using ZAP70 knockout cell lines can identify genes that are essential for the survival of ZAP70-deficient cells. These genes could serve as potential drug targets for treating IMD88 or for selectively eliminating autoreactive T cells. For example, a screen might reveal that ZAP70-deficient cells are dependent on alternative kinases, such as Syk, for survival, suggesting that Syk inhibitors could be used to treat ZAP70-mutant lymphomas.